OPT 0.60% 83.5¢ opthea limited

Ann: Opthea reports positive data from Phase 1 wet AMD Trial-OPT.AX, page-5

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,951 Posts.
    lightbulb Created with Sketch. 189
    Drugs in this area are judged successful if they prevent deterioration. On that measure the results albeit from a small sample are impressive

    "Overall, a majority of patients (16/19 evaluable at week 12) maintained or gained vision by week 12 compared to baseline and the other 3 patients that all received combination OPT-302 + Lucentis® therapy did not lose more than 3 letters (range -2 to -3 letters). The mean gain in visual acuity overall from baseline at week 12 in treatment naïve patients who received OPT-302 + Lucentis® was 16.5 letters (n=4) and 9.5 letters in the 2 mg OPT-302 + Lucentis® dose cohort (n=2). The mean visual acuity gain from baseline at week 12 in patients who showed a sub-optimal response to prior anti-VEGF-A therapy was 4 letters with combination OPT-302 + Lucentis® (n=10 evaluable patients; mean number of prior treatment injections = 10.5, range 3 – 55)."

    So what`s it worth?? OPT 302  from these results improves patients treated for VEGF A alone and I`m sure Lucentis and Opthotech will have taken note.
 
watchlist Created with Sketch. Add OPT (ASX) to my watchlist
(20min delay)
Last
83.5¢
Change
-0.005(0.60%)
Mkt cap ! $1.027B
Open High Low Value Volume
85.5¢ 85.5¢ 82.0¢ $11.20M 13.42M

Buyers (Bids)

No. Vol. Price($)
1 13018 83.0¢
 

Sellers (Offers)

Price($) Vol. No.
84.0¢ 3897 1
View Market Depth
Last trade - 16.10pm 31/10/2024 (20 minute delay) ?
OPT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.